RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has launched a double-blinded, placebo-controlled Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate in a third indication -- improving the plasma lipid profiles of patients treated with Simvastatin, the most widely prescribed, now generic, cholesterol-lowering drug.
